Proactive Investors - Run By Investors For Investors

First data for Redx Pharma’s RXC006 fibrosis candidate shows compound has “great potential”

The data showed RXC006 was able to suppress the Wnt pathway, which is widely believed to be heavily involved in the scarring process associated with lung fibrosis
fibrosis
Along with cancer, fibrosis is one of Redx’s core focus areas

The first pre-clinical data for Redx Pharma Plc’s (LON:REDX) RXC006 drug candidate has suggested that the compound has “great potential” as a fibrosis treatment.

RXC006 is what’s known as a Porcupine inhibitor. They work by dialling down the Porcupine protein, which is the control switch for the Wnt pathway – widely believed to be heavily involved in the scarring process in the lung typical of idiopathic pulmonary fibrosis.

READ: Redx hails new fibrosis candidate

This first batch of in-vivo data showed that the compound was “highly effective” in suppressing the Wnt pathway and lung fibrosis.

Suppression of both liver and kidney fibrosis has also been shown in animal models.

“The data suggests that RXC006 has great potential to treat fibrosis in human patients,” said chief scientific officer Richard Amer.

“Redx are progressing RXC006 towards the clinic for the treatment of Idiopathic Pulmonary Fibrosis and plan to initiate first in man clinical trials during 2020.”

View full REDX profile View Profile

Redx Pharma Plc Timeline

Related Articles

copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
Cyrptocurrencies
June 27 2018
Lancor Scientific is aiming to carry out an initial coin offering by issuing Medici, a new currency based on Ethereum to help Tumour Trace to fund further development
cancerous cells
April 15 2019
The company’s cancer treatment is based on work undertaken by John Beard, a professor of embryology at Edinburgh University nearly 100 years ago

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use